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Efficacy of a T Cell-Biased 
Adenovirus Vector as a Zika Virus 
Vaccine
Brianna L. Bullard  1, Brigette N. Corder1, Matthew J. Gorman2, Michael S. Diamond  2 & 
Eric A. Weaver1
Zika virus (ZIKV) is a major public health concern due to the risk of congenital Zika syndrome in 
developing fetuses and Guillain-Barre syndrome in adults. Currently, there are no approved vaccines 
available to protect against infection. Adenoviruses are safe and highly immunogenic vaccine 
vectors capable of inducing lasting humoral and cellular immune responses. Here, we developed two 
Adenovirus (Ad) vectored Zika virus vaccines by inserting a ZIKV prM-E gene expression cassette 
into human Ad types 4 (Ad4-prM-E) and 5 (Ad5-prM-E). Immune correlates indicate that Ad5-prM-E 
vaccination induces both an anti-ZIKV antibody and T-cell responses whereas Ad4-prM-E vaccination 
only induces a T-cell response. In a highly lethal challenge in an interferon α/β receptor knockout 
mice, 80% of Ad5 vaccinated animals and 33% of Ad4 vaccinated animals survived a lethal ZIKV 
challenge, whereas no animals in the sham vaccinated group survived. In an infection model utilizing 
immunocompetent C57BL/6 mice that were immunized and then treated with a blocking anti-IFNAR-1 
antibody immediately before ZIKV challenge, 100% of Ad4-prM-E and Ad5-prM-E vaccinated mice 
survived. This indicates that Ad4-prM-E vaccination is protective without the development of detectable 
anti-ZIKV antibodies. The protection seen in these highly lethal mouse models demonstrate the efficacy 
of Ad vectored vaccines for use against ZIKV.
Zika virus (ZIKV) is a mosquito-borne, positive-stranded RNA virus that belongs to the genus Flavivirus in 
the Flaviviridae family1. This genus also contains other important human pathogens, such as Dengue, West 
Nile, Japanese encephalitis, and yellow fever viruses. ZIKV was first discovered in the Zika forest of Uganda 
in 1947 and believed to cause only asymptomatic or mild infection in humans2. However, the 2015 outbreak 
of ZIKV in Brazil showed higher than historical rates of congenital birth defects in fetuses and babies born to 
ZIKV-infected mothers along with an increase in the rate of Guillain-Barre syndrome in adults3–6. The World 
Health Organization (WHO) declared ZIKV a global public health emergency in February 2016 after an esti-
mated 500,000–1,500,000 suspected cases of ZIKV infection with more than 4,300 cases of microcephaly were 
reported7. This state of emergency has since been lifted, although the importance of ZIKV research and vaccine 
development remains a global priority8.
Although there are no licensed vaccines available to prevent ZIKV infection, much progress has been made 
since 2015. Many vaccine platforms have been explored including traditional platforms such as live-attenuated9–11, 
inactivated12–14, and subunit vaccines15–17. Other platforms include the expression of ZIKV structural and 
non-structural genes in DNA12,14,18–21, mRNA11,22–24, or viral vectors25–29. The precursor-membrane (prM) and 
envelope (E) protein of ZIKV have been the primary structural antigens used in many recombinant vaccines 
and have shown promising results11,12,14,18–28. Importantly, it has been shown that expression of the prM and E 
ZIKV proteins leads to the assembly of ZIKV virus-like particles (VLPs) in vitro30, which could be beneficial in a 
gene-delivery based vaccine platform, as VLPs can induce highly neutralizing antibodies that recognize confor-
mational epitopes on the viral envelope (E) protein.
Adenovirus viral vectors have been shown to induce both strong humoral and cellular immunity31,32. 
Adenovirus type 5 (Ad5) has been the most extensively used vector due to the robust immune response it elicits. 
However, pre-existing immunity to Ad5 has been reported to be as high as 82.5% in Brazil and 70% in the United 
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States33. With high pre-existing immunity to Ad5, other Adenovirus types have been explored. A epidemiolog-
ical study of military recruits in the United States, showed that only 33% had pre-existing immunity to human 
Adenovirus type 4 (Ad4)34. Ad4 has been shown to be effective as a viral vector in vaccination against influenza, 
either alone or in combination with Ad535,36.
In this study, we developed both human Ad5 and Ad4 expressing the ZIKV full-length prM-E genes as a 
candidate ZIKV vaccine. Ad5-prM-E elicited both a strong antibody and T-cell response, whereas Ad4-prM-E 
did not induce any detectable anti-ZIKV antibodies but still induced a strong T-cell response. In a lethal ZIKV 
challenge model using an Ifnar−/− mice, Ad5-prM-E provided superior protection to Ad4-prM-E vaccination. 
However, both Ad vectors protected 100% of mice in a challenge model using anti-Ifnar1 blocking antibody. 
These data support the use of Ad vectors as a platform for ZIKV vaccine development.
Results
Construction of replication-defective Adenoviral-vectored vaccines. The full length prM-E genes 
of Zika virus (ZIKV) strain PRVABC59 (Puerto Rico, 2015) were cloned into the E1 region of Ad type 5 (Ad5-
prM-E) or Ad type 4 (Ad4-prM-E) to create a replication-defective vector (Fig. 1A). The Ad5-prM-E vector is 
also E3 deleted to increase cloning capacity. In addition, the Zeocin resistance gene flanked by Frt regions (which 
was used for effective screening of recombinant clone) was left in the Ad4 vector for simplicity. However, this 
gene can be easily removed using FLP recombinase for future studies. These differences should not affect in vivo 
immunogenicity as both of these vectors are replication defective. ZIKV-E protein expression was confirmed in 
both Ad vaccines by western blotting (Fig. 1B). 293 cells were infected at on MOI of 1 for 48 hours and cell lysate 
was collected. No significant difference in ZIKV-E protein expression was detected. Data was collected from three 
separate biological replicates (Fig. 1C).
Antibody response to vaccination. To examine the humoral immunity induced by vaccination, groups 
of C57BL/6 mice were immunized with a single dose of 1010 virus particles (vp) of Ad vaccine (Ad5-prM-E or 
Ad4-prM-E) by the intramuscular route (i.m.) on day 0 (Fig. 2A,B). PBS was used as a vaccination negative 
control. All vaccinated mice were sacrificed on week 8 for immune response analysis. Mice that received single 
priming dose of Ad5-prM-E showed significantly higher levels of anti-ZIKV E protein antibodies as measured by 
ELISA (Fig. 2C) compared to the control PBS-treated mice. However, Ad4-prM-E vaccinated mice did not show 
detectable levels of specific anti-ZIKV-E protein antibodies or neutralizing antibodies (Fig. 2C,D).
To investigate if an Ad prime/boost vaccination strategy would increase immune responses, C57BL/6 mice 
were vaccinated at day 0 with 1010 vp of Ad vaccine, boosted with 1010 vp of the homologous or heterologous 
Ad vaccine on week 6, and sacrificed on week 8 (Fig. 2A,B). Prime/boost strategies utilizing Ad5-prM-E as the 
prime showed significantly higher levels of neutralizing antibodies than control mice (Fig. 2C,D). In contrast, the 
Ad4-prM-E primed mice showed no boosting effect at all.
Ad4-prM-E vaccination does not induce detectable antibodies. To ensure that the lack of anti-
body response during Ad4-prM-E vaccination was not due to infectious differences in the Ad vaccine virus 
stocks, C57BL/6 mice were vaccinated based on infectious units (IFU). The IFU per mL was calculated for both 
Ad5-prM-E and Ad4-prM-E vaccine stocks. An analysis of virus particle (vp) to IFU showed a 2.3-fold differ-
ence between Ad5-prM-E and Ad4-prM-E (Fig. 2E). Mice were then vaccinated with 1010 vp of Ad5-prM-E or 
2.3 × 1010 vp of Ad4-prM-E, resulting in a vaccination dose with equal IFU. In order to evaluate the response to 
vaccination near the predicated peak immune response, mice were euthanized 2 weeks later for immune correlate 
Figure 1. Construction and characterization of Adenovirus-vectored vaccine. (A) The ZIKV strain PRVABC59 
prM-E region with a VSV G signal peptide under the control of a CMV promoter was cloned into the Ad5 
and Ad4 genomes in the E1 region. Ad5 was also deleted for the E3 region. (B) A representative western blot 
comparing the levels of ZIKV-E protein expression from Ad4-prM-E and Ad5-prM-E infected 293 cells infected 
at an MOI of 1. GAPDH is used as a cellular control. (C) The ratio of ZIKV-E protein to GAPDH of western 
blots from C. The western blot data represents three separate biological replicates (n.s. not significant, two-tailed 
t test). Data are expressed as the mean with standard error (SEM).
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analysis. Again, Ad4-prM-E vaccination did not result in any detectable anti-ZIKV antibodies as measured by 
ELISA (Fig. 2F) or plaque reduction neutralization test (Fig. 2G). This data indicates that the lack of antibody 
development in Ad4-prM-E vaccinated mice is not due to differences in vaccine stock infectivity.
T-cell responses after vaccination. The T-cell response against the tested vaccine strategies and ZIKV 
infection was examined using an IFN-γ enzyme-linked immunospot assay (ELISPOT). Splenocytes were iso-
lated and incubated with 15-mer peptides with 13 amino acid overlap spanning the entire E protein of ZIKV 
strain PRVABC59. Of the 164 tested peptides, 16 peptides were positive for a response (Fig. 3; Table. S1). A 
response was considered positive if it was 4 times the response of the PBS sham vaccinated mice (Fig. 3A). Both 
Ad5-prM-E and Ad4-prM-E vaccination induced a significant T-cell response against ZIKV E protein peptides 
(Fig. 3B). Peptide 1 and 2 induced the strongest T-cell response in all Adenovirus vaccinated animals (Fig. 3C) 
and encompassed the previously identified immunodominant CD8+ T-cell epitope E4–12 (position number E294–
302 on the polypeptide)37,38. A strong T-cell response was generated against this epitope after a single shot of 
either Ad4-prM-E or Ad5-prM-E and was similar in intensity to the T-cell response seen after being boosted 
with either the homologous or heterologous Ad vaccine. Therefore, the prime/boost strategy and Adenovirus 
serotype-switching strategy did not significantly increase the T cell responses as judged by IFN-γ ELISPOT.
Vaccine protection to lethal ZIKV infection in mice. Initially, protection was examined in 
Ifnar1−/−mice on a C57BL/6 background, which are vulnerable to ZIKV infection39. Since no significant differ-
ences were seen in immune correlates between vaccination based on virus particles or infectious units (Fig. 2), 
challenge studies were carried out with 1010 vp per mouse. Ifnar1−/− mice were primed via i.m. injection at day 
0 with 1010 vp Ad4-prM-E or Ad5-prM-E, or PBS as a sham control. Animals were boosted with the same dose 
of vaccine at week 3 and challenged at week 7 with 106 FFU of mouse-adapted ZIKV strain 4152540 (Fig. 4A). A 
comparison of the genetic differences between the PRVABC59 vaccination strain and the Dakar 41525 challenge 
strain can be seen in Supplementary Fig. 1. Studies have identified a single ZIKV serotype indicating that one 
Figure 2. Antibody response from Adenovirus vaccination. (A–D) C57BL/6 mice (n = 5) were immunized 
with either Ad5-prM-E, Ad4-prM-E, or sham vaccine according to the timeline in (A) and at the indicated 
dose via the i.m. route (B). ZIKV E protein specific antibodies were measured using an ELISA in (C) and 
neutralization titer (PRNT50) was determined by plaque reduction assay in (D) (*p < 0.05; **p < 0.01, 
***p < 0.001, ****p < 0.0001; one-way ANOVA with Bonferroni multiple comparisons). To ensure that the 
undetectable antibody response to Ad4-prM-E vaccination was not sue to differences in infectivity of Ad 
vaccine virus stocks, the virus particle (vp) to infectious unit (IFU) ratio was determined (E). C57BL/6 mice 
(n = 5) were then vaccinated with an equal IFU dose and the antibody response measured via ELISA (F) and 
plaque reduction assay (G) **p < 0.01; one-way ANOVA with Bonferroni multiple comparisons). Data are 
expressed as the mean with standard error (SEM).
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ZIKV vaccine antigen should protect against all ZIKV strains13,41. After challenge, mice were monitored and 
euthanized when a weight loss of 25% or more was detected. Ad5-prM-E primed and boosted mice showed an 
80% survival rate and Ad4-prM-E primed/boost mice had a 33% survival rate whereas all of the sham vaccina-
tion animals succumbed by day 7 (Fig. 4B,C; Fig. S2A). ZIKV viremia in mice peaks between day 3–4 post42,43, 
so animals were bled 4 days after infection to determine viremia using RT-qPCR (Fig. 4D). Ad5-prM-E animals 
showed a highly significant decrease in viremia (p < 0.001). Ad4-prM-E vaccination also decreased viremia com-
pared to those in sham vaccinated mice. In addition, a plaque assay was performed to determine infectious ZIKV 
levels in sera. Both Ad4-prM-E and Ad5-prM-E vaccination significantly reduced infectious plaque forming 
Figure 3. T-cell epitope mapping in response to vaccination. (A,B) Splenocytes from the vaccinated C57BL/6 
mice (n = 5) were harvested. T-cell epitopes against ZIKV-E protein were mapped using a 164 peptide array of 
15-mers with 13 amino acid overlap spanning the entire ZIKV-E protein. Peptides were considered positive if 
the response was 4 times the sham vaccinated mice. Positive peptides for each vaccination group are indicated 
in (A). The level of response seen against each positive peptide are reported as spot-forming cells (SFC) per 
million splenocytes (B). Peptides 1 and 2 encompass a previously described CD8+ immunodominant T-cell 
epitope37. The T-cell response against this epitope is shown as spot-forming cells (SFC) per million (C) 
(****p < 0.0001; one-way ANOVA with Bonferroni multiple comparisons). Data are expressed as the mean with 
standard error (SEM).
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units in the sera (Fig. S2B). To ensure that the response to vaccination in this immunocompromised mouse is 
intact, immune correlate analyses were performed after priming and boosting of Ifnar1−/− mice. ELISA (Fig. 4E), 
PRNT50 (Fig. 4F), and ELISPOT (Fig. 4G) confirmed a vaccine-induced immune response that was similar to 
wild type C57BL/6 mice.
Due to the immunocompromised nature of the Ifnar1−/− mice, we tested a second challenge model that uti-
lized wild type C57BL/6 mice and a blocking anti-Ifnar1 antibody (MAR1-5A3) administered after vaccination 
but before challenge, which makes naïve mice susceptible to lethal ZIKV infection43. Groups of C57BL/6 mice 
were immunized via the i.m. route with 1010 vp of Ad4-prM-E or Ad5-prM-E, or PBS (Fig. 5A). Mice were 
boosted at week 3 with 1010 vp of Adenoviral vector, either heterologous or homologous to the prime Adenovirus 
type. One day prior to challenge, mice were administered 2 mg of anti-Ifnar1 mAb via i.p. injection. An additional 
0.5 mg of mAb was administered on day 4 post infection to ensure lethal challenge. At week 7, all mice were 
challenged with 106 FFU of mouse adapted ZIKV Dakar strain 41525 and monitored for weight loss (Fig. 5B). 
All Adenoviral vaccinated mice survived challenge, regardless of prime/boost strategy (Fig. 5C). In comparison, 
all sham vaccinated mice showed significant weight loss by day 5 (Fig. 5B). All Adenovirus vaccinated animals 
showed decreased viremia compared to sham vaccinated mice by RT-qPCR (Fig. 5D) and plaque assay (Fig. S2C).
Discussion
Adenoviruses have been widely used as vaccine vectors due to their ability to induce humoral and cellular 
immune responses44–46. Replication-defective Adenovirus vectors have been shown to be safe and well toler-
ated in clinical trials32,47,48. Here we developed replication-defective human Ad5 and Ad4 vectored ZIKV vac-
cines and characterized their immune responses and protection against ZIKV infection. Ad5-prM-E vaccination 
Figure 4. Vaccine protection against challenge in Ifnar1−/− mice. (A–D) Ifnar1−/− mice were immunized 
with 1010 vp of Ad4-prM-E (n = 9), Ad5-prM-E (n = 10), or sham PBS (n = 10) via the i.m. route according to 
the timeline in (A). Two experimental replicates were performed. Mice were boosted with the same vaccine 
and dose at week 3 and then challenged with 106 FFU of mouse-adapted ZIKV strain 41519 at week 7. Weight 
loss was monitored (B) and mice were sacrificed when a 25% weight loss was reached (C). Asterisks indicate 
significance in weight compared to PBS sham vaccinated mice as determined by two-way ANOVA (p < 0.05). 
Survival data was analyzed using a log rank test (***p < 0.001, ****p < 0.0001). Blood was sampled at 4 days 
post infection (d.p.i) to determine the viral load in the sera using RT-qPCR (D) (**p < 0.01; ****p < 0.0001; 
one-way ANOVA). To determine immune correlates in Ifnar1−/− mice, groups (n = 5) were immunized with 
1010 vp of the indicated Ad vaccine and sacrificed 2 weeks later. Sera was used to determine anti-ZIKV IgG 
(E) and neutralizing antibodies (F). In addition, an ELISPOT was performed to determine spot-forming cells 
per million splenocytes against the immunodominant E4–12 epitope (G). ELISA, PRNT50, and ELISPOT are 
analyzed with one-way ANOVA (**p < 0.01, ****p < 0.0001). Data are expressed as the mean with standard error 
(SEM).
www.nature.com/scientificreports/
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induced a strong anti-ZIKV humoral immune response. However, Ad4-prM-E vaccination induced no detect-
able anti-ZIKV antibodies, even with vaccination with an equal IFU dose to the Ad5-prM-E vaccination or in a 
prime-boost strategy.
Vaccination by either Ad5-prM-E and Ad4-prM-E resulted in the development of a T-cell immune response. 
This is important because CD8+ T-cells have been shown to protect against ZIKV infection37,38,49. Notably, 
both Ad vectored vaccines elicited T-cell responses against the immunodominant epitope E4–12. The ability of 
Ad4-prME vaccination to induce significant T-cell response but no detectable antibody response could demon-
strate preferential development of cellular over humoral immune response in Ad4 vectored vaccination. Ad has a 
self adjuvanting property, and the Ad4 and Ad5 vectors may initiate very different cytokine profiles that are highly 
Th1 biased in Ad4 immunized mice but more Th1/Th2 balanced in the Ad5 immunized mice50. A phase I clinical 
trial utilizing Ad4 as an oral, replication-competent vector for H5 influenza vaccination found similar results. 
Participants vaccinated with an Ad4-H5 vector developed robust T-cell responses but failed to seroconvert even 
after 3 vaccinations (11% in vaccinated vs 7% in placebo groups)51. This could indicate that the immune profile of 
a strong T cell response with limited antibody development that we see with our Ad4-prM-E vaccination is not 
limited to mouse models or the ZIKV antigen, but further studies are needed to fully evaluate this.
In the anti-Ifnar1 blockade challenge model, both Ad5-prM-E and Ad4-prM-E vaccinated mice protected 
against weight loss and death. On day 4 post infection, vaccination significantly reduced levels of ZIKV RNA and 
infectious virus in serum. Even in the highly lethal Ifnar1−/− mouse challenge model, the Ad vectored vaccines 
were partially protective. The immunocompromised state of the mice along with the challenge dose made this 
challenge highly stringent. However, as ZIKV infection is not lethal in adult human infection, further studies 
need to be performed to determine if the partial protection in this highly lethal challenge study translates to pro-
tective efficacy in human vaccination.
In conclusion, we constructed two replication-defective Adenovirus (Ad) vectored vaccine candidates by 
inserting the ZIKV structural prM-E genes into the E1 region of human Ad type 4 and Ad type 5. Both vec-
tors have shown promise by protecting against ZIKV infection in a lethal antibody blockade challenge model. 
However, immune correlates indicate that Ad4-prM-E vaccination established a different immune profile than 
Ad5-prM-E vaccination. The ability of Ad4-prM-E vaccination to induce a strong T-cell response with unde-
tectable levels of antibody, while Ad5-prM-E vaccination induces both strong antibody and T-cell responses, 
warrants further investigation. A comprehensive cytokine/chemokine and cellular profile analysis may elucidate 
these mechanisms. Due to the potential for antibody dependent enhancement (ADE) of Dengue virus from ZIKV 
antibodies22,52,53, the lack of antibody development in Ad4-prM-E vaccination could be explored as a potentially 
safer vaccine platform. Our study highlights the significant differences in immune profiles between these two Ad 
vectors and supports further investigation of the use of Ad vectors as a platform for ZIKV vaccine development.
Figure 5. Vaccine protection against challenge in C57BL/6 mice in anti-Ifnar1 mAb-treated mice. (A–D) 
C57BL/6 mice (n = 5) were immunized with 1010 vp of Adenovirus vectored vaccine or sham PBS via i.m. 
injection according to the timeline in (A). Mice were boosted with at week 3 with the indicated vaccine. At 
week 7, mice were challenged with 106 FFU of mouse-adapted ZIKV strain 41525. One day prior to infection, 
2 mg of mouse anti-Ifnar1 was administered via i.p. injection to create a lethal challenge model. Another 0.5 mg 
of antibody was administered on 4 days post infection (d.p.i). Weight loss was monitored (B) and mice were 
sacrificed at 25% weight loss (C). Asterisks indicate significant in weight compared to PBS sham vaccinated 
mice as determined by two-way ANOVA (p < 0.05). Blood was sampled at 4 d.p.i to determine the viral load in 
the sera using qPCR (D) (****p < 0.0001; one-way ANOVA). Data are expressed as the mean with standard error 
(SEM).
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Materials and Methods
Ethics statement. B6(Cg)-Ifnar1tm1.2Ees/J Ifnar1−/− mice were purchased from Jackson Laboratories 
and a breeding colony was established. Female C57BL/6 J mice ages 6–8 weeks were purchased from Jackson 
Laboratory. Mice were housed in Life Sciences Annex building on the University of Nebraska – Lincoln (UNL) 
campus under the Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) guidelines. The protocols were approved by the UNL Institutional Animal Care and Use Committee 
(IACUC) (Project ID 1448: Viral Vectored Flavivirus Vaccines). All animal experiments were carried out accord-
ing to the provisions of the Animal Welfare Act, PHS Animal Welfare Policy, the principles of the NIH Guide for 
the Care and Use of Laboratory Animals, and the policies and procedures of UNL. All immunizations and bleeds 
were performed under ketamine and xylazine induced anesthesia.
Viruses. Zika virus (ZIKV) strain PRVABC59 (ZIKV-PR; Puerto Rico, 2015) was provided by the Biodefense 
and Emerging Infections Research Resources Repository (BEI Resources). ZIKV strain Dakar 41525 was adapted 
for mice by passage in Rag1−/− mice40. Viral stocks of ZIKV strain PRVABC59 were grown on C6/36 cells and 
collected after 7 days. Viral stocks of mouse-adapted ZIKV strain Dakar 41525 were grown on Vero cells and 
harvested after 3 days. Supernatant was collected and clarified by centrifugation at 350 g for 10 min. Aliquots were 
stored at −80 °C. The virus was quantified by plaque assay or focus forming assay (FFA)39.
Recombinant adenovirus type 5 plasmid construction. The full prM-E gene from ZIKV strain 
PRVABC59 was codon-optimized for human gene expression, and the VSV G signal sequence was added to the 
N-terminus of the protein. The DNA was synthesized by GenScript and kindly provided by Dr. Asit Pattnaik and 
cloned in a pCI-Neo mammalian expression vector. Recombinant Adenovirus 5 was created using the AdEasy 
Adenoviral Vector System (Agilent). Briefly, to introduce unique restriction enzyme sites for downstream cloning, 
the prM-E region was amplified by PCR from the pCI-Neo DNA plasmid vaccine using the Q5 High-Fidelity 
2X Master Mix (NEB). It was cloned into pCR-Blunt using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen) 
for sequence confirmation. After confirmation, the gene was cloned into the pShuttle-CMV supplied in the 
AdEasy kit using T4 DNA ligase (NEB). This shuttle contains both a CMV promoter and a SV40 PolyA sig-
nal. The pShuttle-CMV-prM-E was linearized and transformed into BJ5183 electrocompetent cells with the 
pAdEasy-1 vector (Adenovirus type 5) to undergo homologous recombination. This recombination inserts the 
prM-E expression cassette into the E1 region of the Adenovirus type 5 (Ad5) genome. In addition, this vector is 
also deleted for the E3 region. Recombination was confirmed by restriction digest and a successful recombinant 
was transformed into XL1 cells for midiprep using the Qiagen Plasmid Midi Kit (Qiagen).
Recombinant adenovirus type 4 plasmid construction. The Adenovirus type 4 genome was 
cloned and a shuttle plasmid to replace the E1 region was created as previously described35. Briefly, the com-
plete Adenovirus type 4 (pAd4) genome was cloned into a single low-copy plasmid, and a shuttle plasmid 
(pAd4-recomb-cloner) to replace the E1 region of Ad4 was created using overlapping PCR products. The 
CMV-prM-E-PolyA region from the pShuttle-CMV-prM-E plasmid was amplified using the Platinum PCR 
SuperMix High Fidelity (Invitrogen) and fused to an Frt-Zeo-Frt fragment using overlapping PCR. This fragment 
was then cloned into pCR8/Gw/TOPO for sequence confirmation (Invitrogen). After sequence confirmation, the 
shuttle was linearized and transformed with the pAd4 plasmid into BJ5183 electrocompetent cells for homol-
ogous recombination. Recombinants were screened on kanamycin and zeocin and confirmed with restriction 
digest. A successful recombinant was then transformed into XL1 cells, and plasmid DNA was purified using the 
Qiagen Plasmid Midi Kit (Qiagen).
Recombinant adenovirus virus rescue and purification. The recombinant Adenovirus 5 and 4 
genomes with the ZIKV prM-E insert were linearized and buffer exchanged using a Strataprep PCR purification 
kit (Agilent Technologies). The linearized recombinant gDNA was transfected into 293 cells using the PolyFect 
Transfection Reagent (Qiagen). After virus rescue was observed via plaque formation, cells were harvested and 
virus was released by 3 freeze-thaw cycles. Virus was amplified by sequential passages in 293 cells until a final 
amplification using a Corning 10-cell stack (~6300 cm2). The virus was purified by 2 sequential CsCl ultracentri-
fuge gradients, desalted using Econo-Pac 10DG Desalting Columns (Bio-Rad), and stored at −80 °C in Ad-tris 
buffer (20 mM Tris-HCl, 100 mM NaCl2, 1 mM MgCl2•6H2O, 10% glycerol).
Recombinant adenovirus quantification. After CsCl purification and desalting, the virus particle quan-
tity was determined on a NanoDrop Lite spectrophotometer (Thermo Fisher) with an OD260. The infectious unit 
titer was determined using the QuickTiter Adenovirus Titer Immunoassay Kit (Cell Biolabs, Inc.). Briefly, 293 
cells were infected with serial dilutions of Adenovirus stock in triplicate. After incubation for 48 hours, cells were 
fixed with cold methanol, blocked with PBS with 1% BSA, and then incubated with anti-hexon antibody. Cell 
were washed, incubated with secondary HRP-conjugated antibody, and developed with DAB. Positive cells were 
stained brown and counted to determine the infectious units per mL.
Western blotting. For confirmation of protein expression from the recombinant Adenoviruses, confluent 
293 cells were infected with Ad5-prM-E or Ad4-prM-E at either 500 vp/cell or an MOI of 1. They were incubated 
at 37 °C and 5% CO2 and harvest at 48 hours. Cells were denatured using Laemmli buffer plus 2-mercaptoethanol 
and boiled at 100 °C for 10 minutes. The sample was then passed through a QIAshredder (Qiagen). Sample was 
loaded onto a 12.5% SDS-PAGE gel and separated using electrophoresis. Protein was transferred to a nitrocel-
lulose membrane and blocked for 30 minutes with 5% milk in TBST. The membrane was incubated in mouse 
anti-ZIKV E protein antibody (mAb-0302156; BioFront Technologies) at 1:5000 and mouse anti-GAPDH (sc-
47724; Santa Cruz Biotechnology, Inc.) at 1:2000 in TBST 1% milk overnight at 4 °C. After 3 washes in TBST, 
www.nature.com/scientificreports/
8SCIeNtIfIC RepoRts |         (2018) 8:18017  | DOI:10.1038/s41598-018-35755-z
the membrane was incubated with goat anti-mouse-HRP conjugated antibody (Millipore Sigma) at 1:2000 in 
TBST 1% milk for 1 hour at room temperature. After incubation, the membrane was washed and developed with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).
ZIKV plaque assay. Cell supernatants were serially diluted in DMEM 2% FBS and added to confluent Vero 
cells. After incubation with rocking at 37 °C and 5% CO2 for 1 h, cells were washed once with PBS and 1 mL of 
agar/DMEM overlay was added. Plates were incubated for 4 days at 37 °C and 5% CO2. After 4 days, cells were 
fixed with 10% formaldehyde, the agar plugs removed, and the cell monolayer was stained using crystal violet. 
Plaques were counted and plaque forming unit (PFU) per mL were calculated.
ZIKV foci forming unit assay. Virus stocks were titrated by focus forming assay (FFA) on Vero cells as 
previously described39 and stored in aliquots at −80 °C.
Mouse challenge studies. Female Ifnar1−/− mice (8-9 weeks old) were immunized intramuscularly at day 
0 with 1010 vp of Ad4-prM-E (n = 9), Ad5-prM-E (n = 10), or control PBS (n = 10). Two experimental replicates 
were performed however, after day 4, three mice in the Ad4-prM-E group were lost to unrelated causes due to 
anesthesia complications. Female C57BL/6 mice were immunized intramuscularly at day 0 with 1010 vp of the 
indicated Ad vaccine or control PBS. All mice were boosted at week 3 with 1010 vp of indicated Adenovirus or 
sham vaccine and then challenged at week 7 with 106 FFU of mouse-adapted ZIKV-Dakar 41525 via the intra-
peritoneal (i.p.) route. C57BL/6 mice were administered 2 mg of anti-mouse Ifnar1 mAb (MAR1-5A3, BioXcell) 
via the i.p. route one day before ZIKV infection and given 0.5 mg more at day 4 post infection. All mice were 
monitored daily for weight loss and mice were euthanized at 25% weight loss.
Antibody and T-cell assays. Female C57BL/6 mice were immunized with 1010 vp of indicated Adenovirus 
or control PBS. All immunizations were performed intramuscularly with a 27-gauge needle into both quadriceps 
in two 25 µl injections. At week 6, prime/boost animals were boosted with 1010 vp of indicated Adenovirus. At 
week 8, all animals were terminally bled via a cardiac puncture and spleens were harvested. Sera was isolated from 
whole blood with a BD Microtainer Blood Collection Tube (Becton Dickinson) and used for further ELISA and 
neutralization tests. Splenocytes were harvested for T cell immune assays.
ELISA. Immunolon 4 HBX microtiter 96-well strips (VWR) were coated with 150 ng of recombinant ZIKV E 
protein (Cat #:MBS596088; MyBioSource) in bicarbonate/carbonate coating buffer overnight at 4 °C. The plates 
were blocked with 2.0% BSA in PBS for 2 hours at room temperature (RT). Sera was diluted in 1.0% BSA in PBS 
and incubated for 2 hours at RT. The plates were washed 6X with PBST and incubated with goat anti-mouse-HRP 
antibody (1:2000; Thermo Fisher) in 1.0% BSA in PBS for 1 hour at RT. After washing 4X with PBST and 2X with 
PBS, the plate was developed with 1-Step Ultra TMB-ELISA (Thermo Fisher), and the reaction was stopped with 
2 M sulfuric acid. The OD450 was detected using a SpectraMax i3x Multi-Mode microplate reader (Molecular 
Devices), and the endpoint titer was determined as signal that was two times background values.
ELISPOT. The T-cell epitopes were mapped using a peptide array of the ZIKV strain PRVABC59 E protein 
from BEI resources (Catalog No. NR-50553). This 164-peptide array spans the entire E region and consists of 
15-mers with 12 amino acid overlap. Potential immunogenic peptides were identified using a matrix of pep-
tides pools, and the epitopes were confirmed using individual peptides. Splenocytes were isolated from mice 
using a 40 μm Nylon cell strainer (BD Labware). Red blood cells were lysed using ACK lysis buffer and the sple-
nocytes were resuspended in cRPMI at a concentration of 106 splenocytes/mL. Ninety-six well polyvinylidene 
difluoride-backed plates (MultiScreen-IP, Millipore) coated with 50 μl of anti-mouse IFN-γ mAb AN18 (5 µg/
ml; Mabtech) overnight at 4 °C. Plates were washed and blocked with RPMI at 37 °C for 1 hour. Equal volumes 
(50 µL) of the single-cell suspension splenocytes and peptide (5ug/mL) were added to the wells in duplicate. Plates 
were incubated overnight at 37 °C with 5% CO2. The plates were washed 6X with PBS and incubated with 100 μl 
of biotinylated anti-mouse IFN-γ mAb (1:1000 dilution; Mabtech) diluted in PBS with 1.0% FBS for 1 hour at 
RT. Plates were washed 6X with PBS and incubated with 100 µl of streptavidin-alkaline phosphatase conjugate 
(1:1000 dilution; Mabtech) diluted in PBS 1.0% FBS. After 1 hour at RT, the plates were washed 6x with PBS. To 
develop, 100 µl of BCIP/NBT (Plus) alkaline phosphatase substrate (Thermo Fisher) was added to each well and 
development was stopped by washing several times in dH2O. The plates were air dried and spots were counted 
using an automated ELISpot plate reader (AID iSpot Reader Spectrum). Results are expressed as spot-forming 
cells (SFC) per 106 splenocytes.
qPCR for viral load quantification. Challenged mice were bled from the submandibular vein at day 4 
post infection and sera was isolated. RNA from sera was extracted using the PureLink Viral RNA/DNA Mini 
Kit according to manufacturer’s instructions (Invitrogen). Real time RT-qPCR was performed using the Luna 
Universal Probe One-Step RT-qPCR Kit (NEB). It was run on a QuantStudio 3 Real-Time PCR System (Applied 
Biosystems) using the Luna kit cycling conditions (55 °C for 10 min, 95 °C for 1 min, and 40 cycles of 95 °C for 
10 s and 60 °C for 1 min). Results were compared to a standard curve created using ZIKV RNA extracted from 
a known quantity of infectious virus. Unamplified samples were set at the limit of detection (100 FFU equiv-
alent/mL). The following primer probe set was used: 1183 F: 50-CCACCAATGTTCTCTTGCAGACATATTG
-30; 1268 R: 50-TTCGGACAGCCGTTGTCCAACACAAG-30; and probes (1213 F):  5 ′FAM/
AGCCTACCTTGACAAGCAGTC/BHQ1–3′22.
Plaque reduction neutralization assay. Mouse sera was heat-inactivated at 56 °C for 30 min. Sera then 
was diluted 2-fold in DMEM 2% FBS and incubated with 50 PFU of ZIKV strain PRVABC59 for 2 hours at 37 °C 
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and 5% CO2. This was then added to a 24-well plate of confluent Vero cells. The plaque assay was continued as 
described above.
Statistical analysis. GraphPad Prism software was used to analyze all data. Data are expressed as the mean 
with standard error (SEM). Survival curves were analyzed using the log rank test and weight loss was analyzed 
using two-way ANOVA multiple comparison test. ELISA, PRNT50, T-cell data, and viral burden were analyzed 
using one-way ANOVA with Bonferroni multiple comparisons. A p value < 0.05 was considered statistically sig-
nificant (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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